ORAC has been a trusted in-vitro measure of antioxidant potential for more than a decade. However, like any in-vitro test, it does not describe potential in-vivo performance. Cell-based assays are valuable tools in bio-medical research and provide vital pre-clinical information about product toxicity, mechanisms of action, and dose response.
The CAA test has two important phases. In Phase 1, the sample is tested for cell toxicity. We determine at what concentrations the sample is non-toxic to the cells.Only these concentrations are used in the next phase. In Phase 2, safe concentrations of the sample are tested to measure the antioxidant performance of the sample. This phase establishes both the ability of the cell to absorb the sample substance (bioavailability) and the antioxidant performance of the sample absorbed by the cell (efficacy). The result is a simple pre-clinical snapshot of biological performance.
Consumers are demanding more information about how their nutrition products work and food and nutrition companies are looking for valid and reliable ways to provide it to them. While the ultimate goal might be evidence from a clinical study, pre-clinical assays are important, practical, and affordable alternatives for consumer products.
The ORAC CAA test combination is also valuable for product R&D, formulation optimization, and screening for more advanced investigation.